Stocks on the Move: SINA Corporation (NASDAQ:SINA), JPMorgan Chase & Co. (NYSE:JPM), Renren (NYSE:RENN), Inovio Pharmaceuticals (NASDAQ:INO), Rite Aid Corporation (NYSE:RAD)

SINA Corporation (NASDAQ:SINA) shares moved down -0.30% in last trading session and ended the day at $47.23. SINA Gross Margin is 61.60% and its has a return on assets of 1.90%. SINA Corporation (NASDAQ:SINA) quarterly performance is 7.56%.

Vetr cut shares of SINA Corporation (NASDAQ:SINA) from a hold rating to a sell rating in a research report released on Monday morning, AnalystRatings.NET reports. Vetrcurrently has $49.16 target price on the stock.

JPMorgan Chase & Co. (NYSE:JPM) ended the last trading day at $58.92. Company weekly volatility is calculated as 2.39%. JPMorgan Chase & Co. (NYSE:JPM) showed a weekly performance of -10.17%.

JPMorgan Chase & Co. (NYSE:JPM) said that, it has signed a letter of intent to develop a new regional campus in Plano’s Legacy West to bring 6,000 North Texas employees.

On 08 January, Renren Inc. (NYSE:RENN) shares moved down -1.43% and was closed at $3.45. RENN EPS growth in last 5 year was 19.20%. Renren Inc. (NYSE:RENN) year to date (YTD) performance is -6.25%.

Renren Inc. (NYSE:RENN) announced the resignation of Mr. Matthew Nimetz and Mr. Katsumasa Niki as directors of the Company, effective December 31, 2015. The board of directors of the Company (the “Board”) is in the process of evaluating candidates for a new independent director of the Company.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) shares advanced 0.17% in last trading session and ended the day at $5.76. INO has a return on assets of -11.00%. Inovio Pharmaceuticals, Inc. (NASDAQ:INO) quarterly performance is -3.36%.

On 4 January, Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced it has appointed Prakash Bhuyan, M.D, Ph.D., as Vice President, Clinical Development. Dr. Bhuyan will lead the clinical development of Inovio’s programs to treat HPV-related pre-cancers (dysplasia). Inovio will take VGX-3100, its treatment for cervical dysplasia caused by the human papillomavirus (HPV), into a phase 3 registration study this year. He will report to Dr. Mark Bagarazzi, Chief Medical Officer.

Rite Aid Corporation (NYSE:RAD) caters to the Services space. It has a net profit margin of 6.60% and weekly performance is -1.02%. On the last day of trading company shares ended up at $7.76. Rite Aid Corporation (NYSE:RAD) distance from 50-day simple moving average (SMA50) is -1.27%.

On 31 December, Rite Aid Corporation (NYSE:RAD) said that for the four-week period ending December 26, same-store sales decreased 0.1 percent over the prior-year period. The company added that front-end same-store sales rose 0.8 percent, while pharmacy same-store sales (including a negative impact from new generic introductions) fell 0.4 percent over the same period a year ago.